Apnea, Obstructive Sleep disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

OSA MCID: APN008 MIFTS: 68	Apnea, Obstructive Sleep (OSA) Categories: Blood diseases, Mental diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Apnea, Obstructive Sleep

MalaCards integrated aliases for Apnea, Obstructive Sleep:

Name: Apnea, Obstructive Sleep ⁵⁷

Obstructive Sleep Apnea Syndrome ⁵⁷ ¹¹ ⁴² ²⁸ ⁵ ¹⁴

Obstructive Sleep Apnea ¹¹ ⁴² ⁷⁵ ¹⁴ ⁶³ ¹⁶

Sleep Apnea, Obstructive ⁴² ⁴³ ⁷¹

Upper Airway Resistance Sleep Apnea Syndrome ⁴² ⁷¹

Sleep Apnea/hypopnea Syndrome ⁵⁷ ⁴²

Osas ⁵⁷ ⁴²

Sahs ⁵⁷ ⁴²

Osa ⁵⁷ ⁴²

[osahs] - Obstructive Sleep Apnoea-Hypopnea Syndrome ³³

Obstructive Sleep Apnoea Hypopnoea Syndrome ³³

[sahs] - Sleep Apnoea-Hypopnea Syndrome ³³

Obstructive Sleep Apnoea, Paediatric ³³

Sleep Apnea Syndrome, Obstructive ⁴²

Obstructive Sleep Apnoea Syndrome ³³

Osa - [obstructive Sleep Apnoea] ³³

Obstructive Sleep Apnoea, Adult ³³

Sleep Apnea Hypopnea Syndrome ⁴²

[sas] - Sleep Apnoea Syndrome ³³

Sleep Apnea Obstructive ⁵³

Sleep Apnea Syndromes ⁷¹

Sleep Apnoea Syndrome ³³

Apnea, Obstructive ⁴²

Obstructive Apnea ⁴²

Sleep Apnoea Nos ³³

Osa Syndrome ³³

Osahs ⁴²

Characteristics:

Inheritance:

Autosomal dominant ⁵⁷

Classifications:

MalaCards categories:
Anatomical: Mental diseases Respiratory diseases Blood diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Sleep-wake disorders

Sleep-related breathing disorders

Obstructive sleep apnoea

External Ids:

Disease Ontology ¹¹ DOID:0050848

OMIM® ⁵⁷ 107650

ICD9CM ³⁴ 327.23

MeSH ⁴³ D020181

NCIt ⁴⁹ C116337

SNOMED-CT ⁶⁸ 194441007

MedGen ⁴⁰ C0520679

SNOMED-CT via HPO ⁶⁹ 271782001 4103001 44169009 more

EFO ¹⁶ EFO_0003918

ICD11 ³³ 1919233290

UMLS ⁷¹ C0037315 C0520679 C0751761

Sources

Summaries for Apnea, Obstructive Sleep

MedlinePlus Genetics: ⁴² Obstructive sleep apnea is a condition in which individuals experience pauses in breathing (apnea) during sleep, which are associated with partial or complete closure of the throat (pper airway). Complete closure can lead to apnea while partial closure allows breathing but decrease the intake of oxygen (hypopnea).Individuals with obstructive sleep apnea may experience interrupted sleep with frequent awakenings and loud snoring. Repeated pauses in breathing lead to episodes of lower-than-normal oxygen levels (hypoxemia) and a buildup of carbon dioxide (hypercapnia) in the bloodstream. Interrupted and poor quality sleep can lead to daytime sleepiness and fatigue, impaired attention and memory, headaches, depression, and sexual dysfunction. Daytime sleepiness leads to a higher risk of motor vehicle accidents in individuals with obstructive sleep apnea. Obstructive sleep apnea is also associated with an increased risk of developing insulin resistance, which is an inability to regulate blood sugar levels effectively; high blood pressure (hypertension); heart disease; and stroke.

MalaCards based summary: Apnea, Obstructive Sleep, also known as obstructive sleep apnea syndrome, is related to obesity-hypoventilation syndrome and acromegaly, and has symptoms including tremor, back pain and dyspnea. An important gene associated with Apnea, Obstructive Sleep is LEP (Leptin), and among its related pathways/superpathways are Metabolism of proteins and Signal Transduction. The drugs Montelukast and Opium have been mentioned in the context of this disorder. Affiliated tissues include heart, tongue and endothelial, and related phenotypes are anosmia and obstructive sleep apnea

PubMed Health : ⁶³ Obstructive sleep apnea: We all know what it is like to feel tired after a sleepless night because of things like noise, worries or stress. But what if you do actually get enough sleep and still feel absolutely beat the next morning? This is normal for many people with obstructive sleep apnea (OSA): They do not get enough air while they are sleeping (but do not usually notice this), have breathing pauses, and feel very sleepy during the day. In the long term, this increases their risk of developing other illnesses and can have a huge effect on their quality of life.

Disease Ontology: ¹¹ A sleep apnea that is characterized by repeated collapse and obstruction of the upper airway during sleep, which results in reduced airflow (hypopnea) or complete airflow cessation (apnea), oxygen desaturation, and arousals from sleep.

OMIM®: ⁵⁷ Obstructive sleep apnea is a common, chronic, complex disease associated with serious cardiovascular and neuropsychologic sequelae and with substantial social and economic costs (Palmer et al., 2003). (107650) (Updated 08-Dec-2022)

Wikipedia: ⁷⁵ Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder and is characterized... more...

Sources

Related Diseases for Apnea, Obstructive Sleep

Diseases related to Apnea, Obstructive Sleep via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1682)

#	Related Disease	Score	Top Affiliating Genes
1	obesity-hypoventilation syndrome	32.2	LEP IL6 ADIPOQ
2	acromegaly	31.4	LEP INS GHRL ADIPOQ
3	hypercholesterolemia, familial, 1	31.3	INS CRP APOE ACE
4	dermatitis	31.1	TNF IL6 IL1B CXCL8
5	prediabetes syndrome	31.0	LEP INS GHRL CRP ADIPOQ
6	actinomycosis	31.0	TNF CRP ALB
7	graves ophthalmopathy	31.0	TNF IL6 IL1B
8	headache	31.0	TNF HTR2A CXCL8 ALB
9	vascular dementia	31.0	TNF INS IL6 IL1B APOE ACE
10	eclampsia	31.0	TNF REN IL6 EDN1 ALB AGT
11	insulin-like growth factor i	31.0	LEP INS IL6 GHRL
12	abdominal obesity-metabolic syndrome 1	31.0	LEP INS GHRL ADIPOQ
13	hypertrophic cardiomyopathy	31.0	TNF REN MIR486-1 INS IL6 EDN1
14	mitral valve insufficiency	31.0	REN CRP ALB ACE
15	eating disorder	31.0	LEP INS HTR2A HCRT GHRL
16	tricuspid valve insufficiency	31.0	REN EDN1 CRP ALB ACE
17	autonomic neuropathy	30.9	REN INS ALB
18	esophagitis	30.9	TNF IL6 IL1B CXCL8
19	post-traumatic stress disorder	30.9	IL6 IL1B HTR2A HCRT CRP
20	normal pressure hydrocephalus	30.9	HCRT APOE ALB
21	autoimmune disease	30.9	TNF INS IL6 IL1B CRP
22	bronchiolitis	30.9	TNF IL6 IL1B CXCL8 CRP
23	acute asthma	30.9	TNF IL6 CXCL8
24	non-alcoholic steatohepatitis	30.9	TNF LEP INS IL6 IL1B ALB
25	acute kidney failure	30.9	REN IL6 ALB ACE
26	retinal disease	30.8	MIR486-1 INS IL6 ALB
27	nutritional deficiency disease	30.8	LEP IL6 GHRL CRP ALB ADIPOQ
28	diabetic autonomic neuropathy	30.8	REN INS ALB ACE
29	pulmonary disease, chronic obstructive	30.8	TNF MIRLET7D IL6 IL1B CXCL8 CRP
30	juvenile rheumatoid arthritis	30.8	TNF IL6 IL1B CRP
31	renal artery atheroma	30.8	REN ALB ACE
32	amyloidosis	30.8	TNF INS IL6 IL1B CRP APOE
33	periodontitis, chronic	30.8	IL6 IL1B
34	glucose intolerance	30.8	TNF LEP INS IL6 GHRL CRP
35	fibromyalgia	30.8	TNF LEP INS IL6 IL1B HTR2A
36	familial partial lipodystrophy	30.8	LEP INS ADIPOQ
37	amenorrhea	30.8	LEP INS GHRL ADIPOQ
38	gout	30.8	TNF INS IL6 IL1B CXCL8 CRP
39	nerve compression syndrome	30.8	INS IL6 CRP ALB
40	hyperinsulinism	30.8	LEP INS GHRL EDN1 ADIPOQ
41	radiculopathy	30.8	IL6 CXCL8 CRP
42	prostatic hypertrophy	30.8	INS CRP ALB ACE
43	arthropathy	30.8	TNF IL6 IL1B CRP
44	aortic disease	30.8	REN MIR486-1 IL6 IL1B CRP APOE
45	autism spectrum disorder	30.8	TNF LEP IL6 IL1B GHRL ADIPOQ
46	dysthymic disorder	30.8	INS IL6 HTR2A HCRT CRP
47	microvascular complications of diabetes 3	30.7	REN INS ALB ACE
48	hemoglobinopathy	30.7	INS IL6 CRP ALB
49	inflammatory bowel disease 1	30.7	TNF IL6 IL1B
50	systemic scleroderma	30.7	TNF IL6 IL1B EDN1 CXCL8 CRP

Graphical network of the top 20 diseases related to Apnea, Obstructive Sleep:

Sources

Symptoms & Phenotypes for Apnea, Obstructive Sleep

Human phenotypes related to Apnea, Obstructive Sleep:

³⁰

#	Description	HPO Source Accession
1	anosmia ³⁰	HP:0000458
2	obstructive sleep apnea ³⁰	HP:0002870
3	excessive daytime somnolence ³⁰	HP:0001262
4	focal impaired awareness seizure ³⁰	HP:0002384
5	snoring ³⁰	HP:0025267

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Neuro:
anosmia
partial complex seizures

Misc:
hypersomnolence
restless movements during sleep

Resp:
obstructive sleep apnea
snoring

Clinical features from OMIM®:

107650 (Updated 08-Dec-2022)

UMLS symptoms related to Apnea, Obstructive Sleep:

tremor; back pain; dyspnea; apnea; headache; syncope; excessive daytime somnolence; pain; wheezing; chronic pain; sciatica; snoring; sleep disturbances; seizures; cheyne-stokes respiration; coughing; vertigo/dizziness; sleeplessness; labored breathing; insomnia with sleep apnea, unspecified; hypersomnia with sleep apnea, unspecified; disruption of 24 hour sleep wake cycle, unspecified

MGI Mouse Phenotypes related to Apnea, Obstructive Sleep:

⁴⁵ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.34	ACE ADIPOQ AGT ALB APOE CRP
2	muscle	MP:0005369	10.31	ADIPOQ AGT ALB APOE EDN1 HCRT
3	nervous system	MP:0003631	10.3	ADIPOQ AGT APOE EDN1 HCRT HIF1A
4	renal/urinary system	MP:0005367	10.25	ACE ADIPOQ AGT ALB APOE EDN1
5	cardiovascular system	MP:0005385	10.2	ACE ADIPOQ AGT ALB APOE CRP
6	liver/biliary system	MP:0005370	10.18	ACE ADIPOQ AGT ALB APOE HIF1A
7	endocrine/exocrine gland	MP:0005379	10.18	ACE ADIPOQ ALB APOE EDN1 GHRL
8	adipose tissue	MP:0005375	10.16	ACE ADIPOQ AGT APOE GHRL HIF1A
9	neoplasm	MP:0002006	10.14	ACE ADIPOQ ALB HIF1A IL1B IL6
10	digestive/alimentary	MP:0005381	10.07	ALB APOE EDN1 GHRL HIF1A HTR2A
11	behavior/neurological	MP:0005386	10.07	ACE ADIPOQ AGT APOE GHRL HCRT
12	immune system	MP:0005387	9.97	ACE ADIPOQ AGT ALB APOE CRP
13	skeleton	MP:0005390	9.65	ADIPOQ APOE EDN1 HIF1A HTR2A IL1B
14	mortality/aging	MP:0010768	9.47	ACE ADIPOQ AGT ALB APOE EDN1

Sources

Drugs & Therapeutics for Apnea, Obstructive Sleep

PubMed Health treatment related to Apnea, Obstructive Sleep: ⁶³

If you are very overweight , losing weight can help improve sleep apnea . There are also many treatment options that aim to relieve sleep apnea. These include machines that support breathing during the night, surgery , and special aids such as mouth guards. Some of these treatments have been scientifically proven to help people with sleep apnea. Medication is currently not used for the treatment of sleep apnea. There is no scientific evidence that the available medications work. The most effective treatment for severe sleep apnea is called CPAP therapy . CPAP stands for “continuous positive airway pressure.” In this treatment approach, air is taken from the immediate surroundings and blown into your airways at night using low pressure. While you sleep, you wear a breathing mask that is connected to a machine called a respirator. The pressure keeps the upper airways open. People who use this machine have fewer breathing pauses, or even none at all. This can noticeably improve the symptoms such as tiredness during the day. Common side effects include a dry throat and an irritated, sometimes blocked nose .

Drugs for Apnea, Obstructive Sleep (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 398)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Montelukast

Approved

Phase 4

158966-92-8

5281040

Opium

Approved, Illicit

Phase 4

8008-60-4

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Remifentanil

Approved

Phase 4

132875-61-7

60815

Nitric Oxide

Approved

Phase 4

10102-43-9

145068

Acetazolamide

Approved, Vet_approved

Phase 4

59-66-5, 1424-27-7

1986

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

Budesonide

Approved

Phase 4

51333-22-3

5281004 40000 63006

Sorbitol

Approved, Investigational

Phase 4

69-65-8, 50-70-4

453 6251 5780

Xylometazoline

Approved, Investigational

Phase 4

526-36-3

5709

Sodium oxybate

Approved

Phase 4

502-85-2

23663870

Desflurane

Approved

Phase 4

57041-67-5

42113

Losartan

Approved

Phase 4

114798-26-4

3961

Donepezil

Approved

Phase 4

120014-06-4

3152

Hydrochlorothiazide

Approved, Vet_approved

Phase 4

58-93-5

3639

Nebivolol

Approved, Investigational

Phase 4

152520-56-4, 99200-09-6, 118457-14-0

71301

Guanfacine

Approved, Investigational

Phase 4

29110-47-2

3519

Glycopyrronium

Approved, Investigational, Vet_approved

Phase 4

596-51-0, 740028-90-4

3494

Sibutramine

Approved, Illicit, Investigational, Withdrawn

Phase 4

106650-56-0

5210

Levobupivacaine

Approved, Investigational

Phase 4

27262-47-1

92253

Paroxetine

Approved, Investigational

Phase 4

61869-08-7

43815

Atropine

Approved, Vet_approved

Phase 4

101-31-5, 5908-99-6, 51-55-8

3661 154417 174174

Adalimumab

Approved, Experimental

Phase 4

331731-18-1

Furosemide

Approved, Vet_approved

Phase 4

54-31-9

3440

Pantoprazole

Approved

Phase 4

102625-70-7, 138786-67-1

4679

Eplerenone

Approved

Phase 4

107724-20-9

443872

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Tramadol

Approved, Investigational

Phase 4

27203-92-5

33741 5523

Oxycodone

Approved, Illicit, Investigational

Phase 4

76-42-6

5284603

Sevoflurane

Approved, Vet_approved

Phase 4

28523-86-6

5206

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Racephedrine

Approved, Experimental

Phase 4

299-42-3, 90-82-4, 90-81-3

5032 9294 7028

Diphenhydramine

Approved, Investigational

Phase 4

147-24-0, 58-73-1

3100

Zolpidem

Approved

Phase 4

82626-48-0

5732

Promethazine

Approved, Investigational

Phase 4

60-87-7

4927

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4

50-02-2

3003 5743

Ketorolac

Approved

Phase 4

74103-06-3, 66635-83-4

3826

Trazodone

Approved, Investigational

Phase 4

19794-93-5

5533

Neostigmine

Approved, Vet_approved

Phase 4

59-99-4

4456 5824

Phenylephrine

Approved

Phase 4

59-42-7

6041

Sufentanil

Approved, Investigational

Phase 4

56030-54-7

41693

Carbidopa

Approved

Phase 4

28860-95-9

34359 38101

Levodopa

Approved

Phase 4

59-92-7, 63-84-3

6047

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Nitrous oxide

Approved, Vet_approved

Phase 4

10024-97-2

948

Finasteride

Approved

Phase 4

98319-26-7

57363

Buspirone

Approved, Investigational

Phase 4

36505-84-7

2477

Interventional clinical trials:

(show top 50) (show all 2272)

#	Name	Status	NCT ID	Phase	Drugs
1	Comparison of the Pentax AWS® With the Macintosh Laryngoscope for Tracheal Intubation in Patients With Obstructive Sleep Apnea Syndrome: a Randomized Comparative Study	Unknown status	NCT01428570	Phase 4
2	Cost-utility Study of CPAP Treatment in Obstructive Sleep Apnea Patients	Unknown status	NCT01590420	Phase 4
3	Open, Prospective Study for the Validation of the Predictive Value of Upper Airway Segmentation and CFD Analysis on Outcome Parameters of the Mandibular Replacement Appliance (MRA) Therapy in Obstructive Sleep Apnea Hypopnea Syndrome OSAHS) Patients	Unknown status	NCT01524510	Phase 4
4	Acetazolamide as add-on Therapy to Obstructive Sleep Apnea Surgery (ACTOS): a Parallel-group, Double-blind, Placebo-controlled, Randomized Trial	Unknown status	NCT04227093	Phase 4	Acetazolamide;Placebo
5	A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder	Unknown status	NCT01535586	Phase 4
6	Randomised Monocentric -Controlled Study to Evaluate the Efficacy and Stability of Dexmedetomidine Sedation Compared to Propofol Sedation in the Routinely Diagnostic Examination: Drug Induced Sleep Endoscopy	Unknown status	NCT03892122	Phase 4	Propofol Fresenius;Dexmedetomidine
7	A Comparison Between Two Different Oral Appliance Therapies: Somnodent vs Herbst Appliance in Patients With Mild and Moderate OSA	Unknown status	NCT02724865	Phase 4
8	Effect of Treating Sleep Apnea With Oral Appliances in the Elderly: ORACLE Study	Unknown status	NCT02325089	Phase 4
9	Donepezil Treatment for Sleep Apnea Patients: A Double Blind Placebo-Controlled Study	Unknown status	NCT00912457	Phase 4	donepezil;placebo
10	Effects of Continuous Positive Airway Pressure (CPAP) and Nebivolol Treatment on Arterial Blood Pressure and Endothelial Function in Hypertensive OSA Patients.	Unknown status	NCT01771406	Phase 4	Nebivolol
11	Blood Pressure Reduction Induced by Continuous Positive Airway Pressure (CPAP) in Sleep Apnea Patients at High Cardiovascular Risk : A Randomized Controlled Trial Comparing Usual CPAP Care Versus a Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform	Unknown status	NCT01505959	Phase 4
12	Effects of the Continuous Positive Airway Pressure Ventilation on the Prevalence of the Metabolic Syndrome and Cardiac Morpho-Functional Characteristics in Sleep Apnea Syndrome	Unknown status	NCT00517777	Phase 4
13	Effect of Servo-Ventilation on CO2 Regulation and Heart Rate Variability	Unknown status	NCT03890939	Phase 4
14	Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing	Unknown status	NCT00299910	Phase 4	Montelukast
15	Effect of Acetazolamide on Central Sleep Apnea Related to Opium Consumption	Unknown status	NCT02371473	Phase 4	Acetazolamide-placebo;Placebo-acetazolamide
16	Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm	Unknown status	NCT01097967	Phase 4
17	The Effect of Nasal CPAP in Patients With Chronic Fatigue and Sleep-disordered Breathing	Unknown status	NCT01368718	Phase 4
18	Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform for Improving Continuous Positive Airway Pressure (CPAP) Compliance in Low Cardiovascular Risk Sleep Apnea Patients	Unknown status	NCT01796769	Phase 4
19	Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude	Completed	NCT00714740	Phase 4	acetazolamide
20	The Endothelium Dysfunction in Patients of Obstructive Sleep Apnea Syndrome	Completed	NCT01699126	Phase 4	Statin
21	Comparative Study of Effect of Valsartan 160mg Treatment Versus Continuous Positive Airway Pressure on Arterial Blood Pressure in Patients Who Have an Obstructive Sleep Apnea Syndrome and a Weak or Moderate Hypertension.	Completed	NCT00409487	Phase 4	Valsartant treatment
22	Ketamine Infusion for Pediatric Patients With Obstructive Sleep Apnea Syndrome After Tonsillectomy: A Randomized Controlled Trial	Completed	NCT02425202	Phase 4	Ketamine
23	Effect of Combined Use of Tolterodine and Continuous Positive Airway Pressure vs Continuous Positive Airway Pressure Only Treatment on Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome: A Randomized Clinical Trial	Completed	NCT05250245	Phase 4	Tolterodine Tartrate 4 MG
24	Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome (OSAS) in Children	Completed	NCT00912171	Phase 4	budesonide (Aircort 50 nasal spray);montelukast (Singulair)
25	Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome	Completed	NCT00603044	Phase 4	fluticasone furoate
26	Continuous Positive Airway Pressure (CPAP) and Acetazolamide for Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude	Completed	NCT00928655	Phase 4	acetazolamide;placebo
27	Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome	Completed	NCT00560586	Phase 4	Budesonide;placebo
28	Efficacy of Continuous Positive Airway Pressure (CPAP) on Blood Pressure Control of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome (OSAS).	Completed	NCT01508754	Phase 4
29	Differential Effects of Chronic Treatment of OSAS by CPAP and SOMNOsmart2 on Norepinephrine and Blood Pressure	Completed	NCT00633711	Phase 4
30	Does Nasal Decongestion Improve Obstructive Sleep Apnea ?	Completed	NCT00630474	Phase 4	xylometazoline
31	Randomized, Placebo-Controlled Multicenter Trial of the Effects of Orally Administered Xyrem (Sodium Oxybate) and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients	Completed	NCT00086281	Phase 4	Xyrem (X);Zolpidem (Z);Modafinil (M);Placebo (P)
32	PROMAD : Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnea	Completed	NCT01532050	Phase 4
33	SASQT: SensAwake™ Sleep Quality Trial A Study to Test the Efficacy of the SensAwake™ Modification to Automatically Titrating Continuous Positive Airway Pressure to Reduce Wake After Sleep Onset in Patients With Moderate to Severe Obstructive Sleep Apnea.	Completed	NCT00811213	Phase 4
34	Cardiovascular Impact of Obstructive Sleep Apnea in Normotensive Patients and the Effects of Continuous Positive Airway Pressure	Completed	NCT00741520	Phase 4
35	Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function	Completed	NCT04789174	Phase 4	Solriamfetol;Placebo
36	Respiratory Impact of Short Life Agents Used in Balanced Anesthesia on Patients Suffering or Suspected of Obstructive Sleep Apnea (OSA) Syndrome	Completed	NCT02717780	Phase 4	Fentanyl and sevoflurane;Remifentanil and desflurane
37	Phase 4 Study of Losartan in Hypertensive Men and Women With Obstructive Sleep Apnea Before and After Continuous Positive Airway Pressure (CPAP) Treatment	Completed	NCT00701428	Phase 4	Losartan
38	The Impact of Arousal Threshold in Obstructive Sleep Apnea: Donepezil's Effects on the Arousal Threshold and on the Apnea Hypopnea Index	Completed	NCT02264353	Phase 4	Donepezil;placebo
39	A Blinded Crossover Study of the 24 Hour Blood Pressure Response to Treatment of Obstructive Sleep Apnea Associated Hypertension With Nebivolol or Hydrochlorothiazide	Completed	NCT02710071	Phase 4	Nebivolol;Hydrochlorothiazide
40	Double-Blind, Placebo-Controlled, Functional Neuroimaging Study of Armodafinil (200 mg/Day) on Prefrontal Cortical Activation in Patients With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea	Completed	NCT00711516	Phase 4	Armodafinil;Placebo
41	Effects of Continuous Positive Airway Pressure (CPAP) on Early Signs of Atherosclerosis in Patients With Obstructive Sleep Apnea: a Randomized Study	Completed	NCT00400543	Phase 4
42	A Placebo Controlled Double Blinded Crossover Study of the Antihypertensive Efficacy of Guanfacine vs Hydrochlorothiazide in Obstructive Sleep Apnea (OSA) Associated Hypertension	Completed	NCT02699125	Phase 4	Guanfacine;Hydrochlorothiazide
43	Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery And Postoperative Complications In Patients With Obstructive Sleep Apnea Undergoing Bariatric Surgery: A Double-Blind, Randomized Controlled Trial	Completed	NCT03679611	Phase 4	Sugammadex Sodium;Neostigmine
44	The Impact of Venlafaxine on Apnea Hypopnea Index in Patients With Obstructive Sleep Apnea	Completed	NCT02714400	Phase 4	Venlafaxine;Placebo
45	Efficacy of Sibutramine-induced Weight Loss vs. Continuous Positive Airway Pressure (CPAP) in the Treatment of Obese Patients With Obstructive Sleep Apnea	Completed	NCT00729963	Phase 4	Sibutramine
46	The Effect of Trazodone on the Severity of Obstructive Sleep Apnea in Insomnic Stroke Patients With Depression	Completed	NCT04162743	Phase 4	Trazodone;Placebo oral tablet
47	Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome: A Randomized Study	Completed	NCT02295202	Phase 4
48	Dexmedetomidine Added to Propofol for Drug Induced Sleep Endoscopy in Adult Patients With Obstructive Sleep Apnea: A Prospective Randomized Controlled Trial	Completed	NCT03091894	Phase 4	Propofol;Dexmedetomidine
49	Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder	Completed	NCT00518986	Phase 4	armodafinil;placebo
50	Renal Hemodynamics and Tubular Function in Patients With Obstructive Sleep Apnea and Healthy Controls	Completed	NCT00410085	Phase 4	L-NMMA (N-mono.methyl-L-arginine)

Search NIH Clinical Center for Apnea, Obstructive Sleep

Cochrane evidence based reviews: sleep apnea, obstructive

Sources

Genetic Tests for Apnea, Obstructive Sleep

Genetic tests related to Apnea, Obstructive Sleep:

#	Genetic test	Affiliating Genes
1	Obstructive Sleep Apnea Syndrome ²⁸

Sources

Anatomical Context for Apnea, Obstructive Sleep

Organs/tissues related to Apnea, Obstructive Sleep:

MalaCards : Heart, Tongue, Endothelial, Brain, Spinal Cord, Lung, Tonsil

Sources

Publications for Apnea, Obstructive Sleep

Articles related to Apnea, Obstructive Sleep:

(show top 50) (show all 31419)

#	Title	Authors	PMID	Year
1	APOE epsilon 4 allele, cognitive dysfunction, and obstructive sleep apnea in children. ⁶² ⁵⁷	Gozal D...Crabtree VM	17636061	2007
2	Nocturnal sleep apnea/hypopnea is associated with lower memory performance in APOE epsilon4 carriers. ⁶² ⁵⁷	O'Hara R...Murphy GM	16116137	2005
3	APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study. ⁶² ⁵⁷	Gottlieb DJ...Young T	15326239	2004
4	Serum amyloid a in obstructive sleep apnea. ⁶² ⁵⁷	Svatikova A...Somers VK	12952844	2003
5	A whole-genome scan for obstructive sleep apnea and obesity. ⁶² ⁵⁷	Palmer LJ...Redline S	12506338	2003
6	The genetics of sleep apnea. ⁶² ⁵⁷	Redline S...Tishler PV	12531037	2000
7	Familial aggregates in obstructive sleep apnea syndrome. ⁶² ⁵⁷	Guilleminault C...Stoohs R	7781344	1995
8	Is the sleep apnoea/hypopnoea syndrome inherited? ⁶² ⁵⁷	Douglas NJ...Mathur R	8153920	1993
9	Studies in the genetics of obstructive sleep apnea. Familial aggregation of symptoms associated with sleep-related breathing disturbances. ⁶² ⁵⁷	Redline S...Milliman RP	1736754	1992
10	Atrial flutter associated with obstructive sleep apnea syndrome. A case report. ⁶² ⁵⁷	Bartall HZ...Benchimol A	7352787	1980
11	Familial obstructive sleep apnea. ⁶² ⁵⁷		759949	1979
12	Obstructive sleep apnea in Georgia family: is it hereditary? ⁶² ⁵⁷	Elliot J	712965	1978
13	Obstructive sleep apnea in family members. ⁶² ⁵⁷	Strohl KP...Hallett M	211413	1978
14	Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. ⁵⁷	Mojon DS...Mathis J	12003609	2002
15	Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults. ⁵⁷	Kadotani H...Mignot E	11401610	2001
16	Familial predisposition to snoring. ⁵⁷	Teculescu DB...Gaultier C	8153952	1994
17	Familial 'sleep apnea plus' syndrome: report of a family. ⁵⁷	Manon-Espaillat R...Ruff R	3257550	1988
18	Sleeping and breathing. ⁵⁷	Turino GM...Goldring RM	692617	1978
19	The sleep apnea syndromes. ⁵⁷	Guilleminault C...Dement WC	180875	1976
20	[Roles of hypertension and serum leptin in obstructive sleep apnea hypopnea syndrome]. ⁵³ ⁶²	Huang R...Huang XZ	20450544	2010
21	[Study of the level of adiponectin in obstructive sleep apnea-hypopnea syndrome patients]. ⁵³ ⁶²	Zhou L...Xia L	20518291	2010
22	Plasma adiponectin level and sleep structures in children with Prader-Willi syndrome. ⁵³ ⁶²	Joo EY...Jin DK	19912511	2010
23	Effects of nasal continuous positive airway pressure treatment on oxidative stress and adiponectin levels in obese patients with obstructive sleep apnea. ⁵³ ⁶²	de Lima AM...Halpern A	19590157	2010
24	Effects of nasal CPAP treatment on insulin resistance, lipid profile, and plasma leptin in sleep apnea. ⁵³ ⁶²	Cuhadaroglu C...Ece T	19127383	2009
25	Mediators of sympathetic activation in metabolic syndrome obesity. ⁵³ ⁶²	Straznicky NE...Esler MD	18959829	2008
26	Hypoadiponectinemia is related to sympathetic activation and severity of obstructive sleep apnea. ⁵³ ⁶²	Lam JC...Mary SM	19090328	2008
27	The dual role of the orexin/hypocretin system in modulating wakefulness and respiratory drive. ⁵³ ⁶²	Gestreau C...Dutschmann M	18812827	2008
28	Airway inflammation in obstructive sleep apnea: is leptin the missing link? ⁵³ ⁶²	Antonopoulou S...Alchanatis M	18606530	2008
29	Association of sleep apnea severity and obesity with insulin resistance, C-reactive protein, and leptin levels in male patients with obstructive sleep apnea. ⁵³ ⁶²	Kapsimalis F...Gourgoulianis K	18365276	2008
30	Re: Leptin and leptin receptor gene polymorphisms in obstructive sleep apnea syndrome. ⁵³ ⁶²	Hanaoka M...Kubo K	18574304	2008
31	Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome. ⁵³ ⁶²	Nakagawa Y...Funahashi T	18198351	2008
32	[Diagnostic values of serum orexin-A levels in children with obstructive sleep apnea-hypopnea syndrome]. ⁵³ ⁶²	Abulaiti A...Duo LK	19099733	2008
33	Leptin and leptin receptor gene polymorphisms in obstructive sleep apnea syndrome. ⁵³ ⁶²	Hanaoka M...Kubo K	17989154	2008
34	Serum levels of adipocytokines, adiponectin and leptin, in patients with obstructive sleep apnea syndrome. ⁵³ ⁶²	Tokuda F...Yokoyama T	18981626	2008
35	Effect of serum leptin levels on hypercapnic ventilatory response in obstructive sleep apnea. ⁵³ ⁶²	Makinodan K...Kimura H	18073454	2008
36	Frequency of distribution of leptin receptor gene polymorphism in obstructive sleep apnea patients. ⁵³ ⁶²	Popko K...Demkow U	18204169	2007
37	Leptin measurement in urine is a reliable method of monitoring its secretion in patients with obstructive sleep apnea syndrome. ⁵³ ⁶²	Chorostowska-Wynimko J...Gorecka D	18204121	2007
38	Obstructive sleep apnea, daytime sleepiness, and type 2 diabetes. ⁵³ ⁶²	Chasens ER	17570878	2007
39	Reduced levels of adiponectin in sleep apnea syndrome. ⁵³ ⁶²	Masserini B...Orsi E	17033258	2006
40	[A study of the level of serum leptin in patients with obstructive sleep apnea-hypopnea syndrome and obesity and patients with normal body mass]. ⁵³ ⁶²	Wang S...Yu H	16836068	2006
41	Serum adiponectin levels in adult male patients with obstructive sleep apnea hypopnea syndrome. ⁵³ ⁶²	Zhang XL...Su S	16205042	2006
42	[The influence of 3 weeks therapy with continuous positive airway pressure on serum leptin and homocysteine concentration in patients with obstructive sleep apnea syndrome]. ⁵³ ⁶²	Rubinsztajn R...Chazan R	17175979	2006
43	Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome. ⁵³ ⁶²	Ulukavak Ciftci T...Bilgihan A	16088283	2005
44	[Serum leptin concentration and sympathetic activation estimated on the adrenaline and noradrenaline serum concentration in patients with obstructive sleep apnea]. ⁵³ ⁶²	Rubinsztajn R...Chazan R	16454443	2005
45	[The changes and implications of plasma orexin-A levels in patients with obstructive sleep apnea-hypopnea syndrome]. ⁵³ ⁶²	Liao XM...Yu Q	16008971	2005
46	[Serum leptin level in patients with obstructive sleep apnea-hypopnea syndrome]. ⁵³ ⁶²	Wang PJ...Yu Y	16008254	2005
47	Low plasma orexin-A levels were improved by continuous positive airway pressure treatment in patients with severe obstructive sleep apnea-hypopnea syndrome. ⁵³ ⁶²	Sakurai S...Takahashi K	15764751	2005
48	Sleep oxygen desaturation and circulating leptin in obstructive sleep apnea-hypopnea syndrome. ⁵³ ⁶²	Tatsumi K...Kuriyama T	15764749	2005
49	Fat accumulation, leptin, and hypercapnia in obstructive sleep apnea-hypopnea syndrome. ⁵³ ⁶²	Shimura R...Kuriyama T	15705994	2005
50	Interactions between obstructive sleep apnea and the metabolic syndrome. ⁵³ ⁶²	Svatikova A...Somers VK	15663918	2005

Sources

Genes for Apnea, Obstructive Sleep

Genes related to Apnea, Obstructive Sleep (0 elite genes):

(show all 39)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	LEP	Leptin	Protein Coding	13.93	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16008254 15705994 11978920 (more) 12759266 15764749 15124716 18204121 19127383 17989154 14521752 15663918 10899061 10988175 18073454 18204169 17570878 16088283 18606530 18365276 18959829 10988169 18574304 15516536 16836068 18981626 10722859 17189682
2	HCRT	Hypocretin Neuropeptide Precursor	Protein Coding	13.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19099733 15316212 18812827 (more) 15764751 14555569 15627867 16008971
3	ADIPOQ	Adiponectin, C1Q And Collagen Domain Containing	Protein Coding	11.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18198351 16205042 20518291 (more) 18981626 15627868 17033258 19912511 19090328 19590157
4	CRP	C-Reactive Protein	Protein Coding	7.83	DISEASES inferred ¹⁴
5	HTR2A	5-Hydroxytryptamine Receptor 2A	Protein Coding	7.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14720019
6	INS	Insulin	Protein Coding	7.66	DISEASES inferred ¹⁴
7	IL6	Interleukin 6	Protein Coding	7.49	DISEASES inferred ¹⁴
8	REN	Renin	Protein Coding	7.45	DISEASES inferred ¹⁴
9	GHRL	Ghrelin And Obestatin Prepropeptide	Protein Coding	7.17	DISEASES inferred ¹⁴
10	AGT	Angiotensinogen	Protein Coding	7.14	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15387996
11	ACE	Angiotensin I Converting Enzyme	Protein Coding	7.14	DISEASES inferred ¹⁴
12	TNF	Tumor Necrosis Factor	Protein Coding	7.03	DISEASES inferred ¹⁴
13	EDN1	Endothelin 1	Protein Coding	6.76	DISEASES inferred ¹⁴
14	MIR486-1	MicroRNA 486-1	RNA Gene	6.74	DISEASES inferred ¹⁴ ¹⁴
15	HIF1A	Hypoxia Inducible Factor 1 Subunit Alpha	Protein Coding	6.72	DISEASES inferred ¹⁴
16	MIRLET7D	MicroRNA Let-7d	RNA Gene	6.67	DISEASES inferred ¹⁴ ¹⁴
17	ALB	Albumin	Protein Coding	6.42	DISEASES inferred ¹⁴
18	IL1B	Interleukin 1 Beta	Protein Coding	6.38	DISEASES inferred ¹⁴
19	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	6.37	DISEASES inferred ¹⁴
20	APOE	Apolipoprotein E	Protein Coding	6.33	DISEASES inferred ¹⁴
21	IGF1	Insulin Like Growth Factor 1	Protein Coding	6.27	DISEASES inferred ¹⁴
22	IGLON5	IgLON Family Member 5	Protein Coding	6.26	DISEASES inferred ¹⁴
23	GCG	Glucagon	Protein Coding	6.24	DISEASES inferred ¹⁴
24	NR3C2	Nuclear Receptor Subfamily 3 Group C Member 2	Protein Coding	6.21	DISEASES inferred ¹⁴
25	NPPB	Natriuretic Peptide B	Protein Coding	6.16	DISEASES inferred ¹⁴
26	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	6.14	DISEASES inferred ¹⁴
27	ATP12A	ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit	Protein Coding	6.1	DISEASES inferred ¹⁴
28	ATP4A	ATPase H+/K+ Transporting Subunit Alpha	Protein Coding	6.1	DISEASES inferred ¹⁴
29	NOS3	Nitric Oxide Synthase 3	Protein Coding	6.06	DISEASES inferred ¹⁴
30	POMC	Proopiomelanocortin	Protein Coding	6.04	DISEASES inferred ¹⁴
31	BMAL1	Basic Helix-Loop-Helix ARNT Like 1	Protein Coding	6.02	DISEASES inferred ¹⁴
32	RETN	Resistin	Protein Coding	5.97	DISEASES inferred ¹⁴
33	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	5.96	DISEASES inferred ¹⁴
34	CRY1	Cryptochrome Circadian Regulator 1	Protein Coding	5.9	DISEASES inferred ¹⁴
35	PYY	Peptide YY	Protein Coding	5.88	DISEASES inferred ¹⁴
36	BDNF	Brain Derived Neurotrophic Factor	Protein Coding	5.87	DISEASES inferred ¹⁴
37	IL10	Interleukin 10	Protein Coding	5.87	DISEASES inferred ¹⁴
38	ENHO	Energy Homeostasis Associated	Protein Coding	5.86	DISEASES inferred ¹⁴
39	ICAM1	Intercellular Adhesion Molecule 1	Protein Coding	5.85	DISEASES inferred ¹⁴

Sources

Variations for Apnea, Obstructive Sleep

ClinVar genetic disease variations for Apnea, Obstructive Sleep:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	RYR1	NM_000540.3(RYR1):c.10097G>T (p.Arg3366Leu)	SNV	Uncertain Significance	598974	rs137932199	GRCh37: 19:39009932-39009932 GRCh38: 19:38519292-38519292
2	SYNE2	NM_182914.3(SYNE2):c.19624G>T (p.Gly6542Trp)	SNV	Uncertain Significance	598975	rs746433383	GRCh37: 14:64685197-64685197 GRCh38: 14:64218479-64218479

Sources

Expression for Apnea, Obstructive Sleep

Search GEO for disease gene expression data for Apnea, Obstructive Sleep.

Sources

Pathways for Apnea, Obstructive Sleep

Pathways related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

(show all 47)

#	Super pathways	Score	Top Affiliating Genes
1	Metabolism of proteins ⁶⁶ Show member pathways Post-translational protein modification ⁶⁶	13.93	REN LEP INS IL6 HIF1A GHRL
2	Signal Transduction ⁶⁶	13.74	AGT APOE CXCL8 EDN1 GHRL HCRT
3	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	13.03	ACE AGT HIF1A IL6 INS REN
4	IL-9 Signaling Pathways ⁶⁵ Show member pathways Adipocytokines and Insulin Signaling ⁶⁵ Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁵ Development Thrombopoietin-regulated cell processes ²² IL-15 Signaling Pathways ⁶⁵ IL-2 Signaling Pathways ⁶⁵ IL-21 Signaling Pathways ⁶⁵ IL-4 Pathway ⁶⁴ IL-4 Signaling Pathways ⁶⁵ IL-7 Signaling Pathways ⁶⁵ IL-9 Pathway ⁶⁴ Immune response IL-9 signaling pathway ²² Interleukin-9 signaling ⁶⁶	12.84	TNF LEP INS IL6 ADIPOQ
5	Alzheimer's disease and miRNA effects ⁷⁴ Show member pathways Alzheimer's disease ⁷⁴	12.81	TNF INS IL6 IL1B APOE
6	IL-1 Family Signaling Pathways ⁶⁵ Show member pathways IL1 signaling pathway ⁶⁷ Immune response IL-1 signaling pathway ²² Interleukin-1 (IL-1) structural pathway ⁷⁴ Interleukin-33 signaling ⁶⁶ Interleukin-36 pathway ⁶⁶ Mucin expression in CF via TLRs, EGFR signaling pathways ²² Pathogen or Damage-activated C-Type Lectin Receptor Signaling Pathways ⁶⁵	12.6	TNF IL6 IL1B EDN1 CXCL8
7	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.49	TNF IL6 IL1B CXCL8
8	Bacterial infections in CF airways ²² Show member pathways Altered glycosylation of MUC1 in tumor microenvironment ⁷⁴ IL-1 beta-dependent CFTR expression ²² IL1-mediated signaling events ⁶¹ Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²² NTHi-Induced Signaling ⁶⁴ Signal transduction through IL1R ⁷⁴	12.39	CXCL8 IL1B IL6 TNF
9	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.29	TNF IL6 IL1B CXCL8
10	Peptide hormone metabolism ⁶⁶ Show member pathways Glycoprotein hormones ⁶⁶ Metabolism of Angiotensinogen to Angiotensins ⁶⁶ Metabolism of Angiotensinogen to Angiotensins ⁷⁴ Peptide hormone biosynthesis ⁶⁶ Synthesis, secretion, and deacylation of Ghrelin ⁶⁶ thyroid hormone biosynthesis ⁶¹	12.11	REN LEP INS GHRL AGT ACE
11	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	12	CXCL8 HIF1A HTR2A IL1B IL6 TNF
12	ACE Inhibitor Pathway, Pharmacodynamics ⁶⁰ Show member pathways ACE inhibitor pathway ⁷⁴ Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics ⁶⁰ Conversion of angiotensinogen to angiotensin II ⁷⁴ Defective SERPING1 causes hereditary angioedema ⁶⁶ Downregulation of ACE2 by SARS-CoV-2 spike protein ⁷⁴ Kinin-Kallikrein pathway ⁷⁴ Non-classical role of vitamin D ⁷⁴ RAS and bradykinin pathways in COVID-19 ⁷⁴ Renin-angiotensin-aldosterone system (RAAS) ⁷⁴ SARS-CoV-2 and ACE2 receptor: molecular mechanisms ⁷⁴	11.99	TNF REN AGT ACE
13	Spinal cord injury ⁷⁴	11.99	TNF LEP IL6 IL1B CXCL8
14	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.96	TNF IL6 IL1B HIF1A CXCL8
15	Senescence and autophagy in cancer ⁷⁴	11.94	INS IL6 IL1B CXCL8
16	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.89	LEP INS IL6 ADIPOQ
17	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.79	CRP CXCL8 HIF1A IL6
18	Burn wound healing ⁷⁴	11.77	TNF IL6 IL1B CXCL8
19	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.73	TNF IL6 IL1B
20	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.71	TNF IL6 CRP
21	Th17 cell differentiation pathway ⁷⁴	11.69	IL6 IL1B HIF1A
22	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.68	TNF IL6 IL1B CXCL8
23	HIF-1-alpha transcription factor network ⁶¹	11.66	LEP HIF1A EDN1
24	miRNAs involvement in the immune response in sepsis ⁷⁴	11.64	TNF IL6 CXCL8
25	IL 10 signaling pathway ⁶⁷	11.64	TNF IL6 IL1B
26	AP-1 transcription factor network ⁶¹	11.6	IL6 HIF1A EDN1 CXCL8 AGT
27	ATF-2 transcription factor network ⁶¹	11.59	INS IL6 CXCL8
28	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.57	IL6 HIF1A CXCL8
29	Non-genomic actions of 1,25 dihydroxyvitamin D3 ⁷⁴	11.54	TNF IL6 CXCL8
30	Interleukin-10 signaling ⁶⁶	11.54	TNF IL6 IL1B CXCL8
31	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	11.51	TNF IL6 IL1B APOE
32	Monoamine transport ⁷⁴ Show member pathways Serotonin transporter activity ⁷⁴	11.46	TNF IL1B AGT
33	IL-10 Pathway ⁶⁴	11.36	TNF IL6 IL1B
34	Lung fibrosis ⁷⁴	11.35	TNF IL6 IL1B EDN1 CXCL8
35	Development and heterogeneity of the ILC family ⁷⁴	11.32	IL1B IL6 TNF
36	Adipogenesis ⁷⁴	11.28	TNF LEP INS IL6 HIF1A AGT
37	Cytokines and inflammatory response ⁷⁴	11.27	TNF IL6 IL1B
38	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway ⁷⁴	11.27	CXCL8 IL1B IL6 TNF
39	Development_Leptin signaling via JAK/STAT and MAPK cascades ²² Show member pathways phospho-PLA2 pathway ⁶⁶	11.26	CRP EDN1 HIF1A LEP
40	Immune infiltration in pancreatic cancer ⁷⁴	11.23	TNF IL6 CXCL8
41	Prostaglandin signaling ⁷⁴	11.2	TNF IL6 IL1B CXCL8
42	Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics ⁶⁰	11.08	LEP INS GHRL
43	Transcription factor regulation in adipogenesis ⁷⁴	11.08	TNF LEP IL6 ADIPOQ
44	Nonalcoholic fatty liver disease ⁷⁴	11.02	TNF LEP INS IL6 ADIPOQ
45	Overview of nanoparticle effects ⁷⁴	10.84	TNF IL6 CXCL8 CRP
46	COVID-19 adverse outcome pathway ⁷⁴	10.75	IL6 CXCL8 AGT
47	Cells and molecules involved in local acute inflammatory response ⁷⁴ Show member pathways IL8-mediated signaling events ⁶¹	10.39	TNF IL6 CXCL8

Sources

GO Terms for Apnea, Obstructive Sleep

Cellular components related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	10.16	ACE ADIPOQ AGT ALB APOE CRP
2	extracellular space	GO:0005615	9.83	ACE ADIPOQ AGT ALB APOE CRP

Biological processes related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

(show top 50) (show all 64)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	10.5	CRP CXCL8 HIF1A IL1B IL6 INS
2	positive regulation of cell population proliferation	GO:0008284	10.45	AGT EDN1 HTR2A IL1B IL6 INS
3	negative regulation of gene expression	GO:0010629	10.36	TNF INS HIF1A EDN1 CXCL8 APOE
4	positive regulation of MAPK cascade	GO:0043410	10.35	TNF LEP INS IL6 GHRL
5	defense response to Gram-positive bacterium	GO:0050830	10.33	TNF IL6 IL1B CRP
6	positive regulation of DNA-binding transcription factor activity	GO:0051091	10.33	EDN1 IL1B IL6 TNF
7	positive regulation of cytosolic calcium ion concentration	GO:0007204	10.33	HTR2A HCRT GHRL EDN1 AGT
8	positive regulation of inflammatory response	GO:0050729	10.32	ACE AGT TNF IL1B
9	positive regulation of interleukin-6 production	GO:0032755	10.31	TNF LEP IL6 IL1B
10	positive regulation of cold-induced thermogenesis	GO:0120162	10.31	LEP HCRT GHRL ADIPOQ
11	positive regulation of peptidyl-tyrosine phosphorylation	GO:0050731	10.3	IL6 HTR2A AGT ADIPOQ
12	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	10.29	TNF LEP INS AGT
13	positive regulation of NF-kappaB transcription factor activity	GO:0051092	10.29	TNF INS IL6 IL1B AGT
14	positive regulation of MAP kinase activity	GO:0043406	10.27	TNF IL1B HTR2A EDN1
15	response to lipopolysaccharide	GO:0032496	10.27	TNF REN IL1B EDN1 ACE
16	response to xenobiotic stimulus	GO:0009410	10.26	TNF REN HTR2A EDN1 ADIPOQ ACE
17	cellular response to xenobiotic stimulus	GO:0071466	10.24	ADIPOQ EDN1 IL1B REN
18	glucose homeostasis	GO:0042593	10.22	ADIPOQ HIF1A IL6 INS LEP
19	response to hypoxia	GO:0001666	10.22	ACE ADIPOQ EDN1 HIF1A LEP TNF
20	acute-phase response	GO:0006953	10.21	INS IL6 CRP
21	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	10.2	TNF LEP IL6
22	negative regulation of endothelial cell proliferation	GO:0001937	10.2	TNF GHRL APOE
23	regulation of insulin secretion	GO:0050796	10.2	IL1B IL6 LEP TNF
24	negative regulation of MAP kinase activity	GO:0043407	10.19	IL1B APOE AGT ADIPOQ
25	positive regulation of vascular endothelial growth factor production	GO:0010575	10.18	IL6 IL1B HIF1A
26	eating behavior	GO:0042755	10.18	LEP HCRT ACE
27	positive regulation of cytokine production involved in inflammatory response	GO:1900017	10.17	HIF1A IL6 TNF
28	negative regulation of neurogenesis	GO:0050768	10.17	TNF IL6 IL1B
29	positive regulation of insulin receptor signaling pathway	GO:0046628	10.16	LEP INS AGT
30	positive regulation of nitric oxide biosynthetic process	GO:0045429	10.15	TNF IL1B EDN1 AGT
31	regulation of blood pressure	GO:0008217	10.15	REN LEP EDN1 AGT ACE
32	positive regulation of glycolytic process	GO:0045821	10.14	INS HTR2A HIF1A
33	regulation of vasoconstriction	GO:0019229	10.14	EDN1 AGT ACE
34	vasodilation	GO:0042311	10.14	TNF INS APOE AGT
35	positive regulation of glial cell proliferation	GO:0060252	10.13	TNF IL6 IL1B
36	positive regulation of mitotic nuclear division	GO:0045840	10.13	EDN1 IL1B INS TNF
37	positive regulation of interleukin-8 production	GO:0032757	10.13	TNF LEP IL6 IL1B ADIPOQ
38	negative regulation of lipid catabolic process	GO:0050995	10.12	TNF INS IL1B
39	positive regulation of chemokine production	GO:0032722	10.12	TNF IL6 IL1B HIF1A
40	positive regulation of membrane protein ectodomain proteolysis	GO:0051044	10.1	APOE IL1B TNF
41	negative regulation of glucose import	GO:0046325	10.09	TNF LEP ACE
42	artery smooth muscle contraction	GO:0014824	10.07	HTR2A EDN1 AGT
43	positive regulation of cytokine production	GO:0001819	10.06	TNF LEP INS IL1B AGT
44	positive regulation of fever generation	GO:0031622	10.03	TNF IL1B
45	positive regulation of neuroinflammatory response	GO:0150078	10.03	TNF IL6 IL1B
46	positive regulation of dendritic spine maintenance	GO:1902952	10.02	INS APOE
47	sequestering of triglyceride	GO:0030730	10.02	TNF IL1B
48	regulation of transmission of nerve impulse	GO:0051969	10.02	GHRL AGT
49	glucose metabolic process	GO:0006006	10.02	TNF LEP INS GHRL ADIPOQ
50	blood vessel diameter maintenance	GO:0097746	10.01	EDN1 AGT ACE

Molecular functions related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	signaling receptor binding	GO:0005102	9.85	TNF REN LEP IL6 EDN1 APOE
2	cytokine activity	GO:0005125	9.7	TNF IL6 IL1B EDN1 CXCL8 ADIPOQ
3	hormone activity	GO:0005179	9.36	LEP INS GHRL EDN1 AGT ADIPOQ